Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: Cardiac responses and overall effects

QJM: An International Journal of Medicine

Volumn 104, Issue 11, 2011, Pages 957-970

  Dubrey, S W ^a   Reece, D E ^b   Sanchorawala, V ^c   Hegenbart, U ^d   Merlini, G ^e   Palladini, G ^e   Fermand, J P ^f   Vescio, R A ^g   Blade J ^h   Heffner, L T ⁱ   Hassoun, H ^j   Liu, X ^k   Enny, C ^k   Ramaswami, P ^k   Elsayed, Y ^k   Van De Velde, H ^l   Mortimer, S ^k   Cakana, A ^k   Comenzo, R L ^m  

^a HILLINGDON HOSPITAL   (United Kingdom)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF PAVIA   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k JOHNSON AND JOHNSON   (United States)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PREDNISONE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; BRONCHITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; ESCHERICHIA COLI INFECTION; FALLING; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HOLTER MONITORING; HUMAN; HYPERTENSION; HYPOTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LOBAR PNEUMONIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; ORTHOSTATIC HYPERTENSION; PATIENT SAFETY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIMARY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; SYNCOPE; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84155179285     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr105     Document Type: Article

References (48)

1. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 2007; 5:179-87.
2. Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. Contrib Nephrol 2007; 153:195-210.
3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898-909.
4. Dubrey S, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996; 125:481-4.
5. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
6. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93:1062-6.
7. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008; 23:941-51.
8. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008; 19(Suppl. 4):iv63-6.
9. Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009; 88:347-50.
10. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140:85-93.
11. Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, et al. Role of NT-ProBNP to assess the adequacy of treatment response in AL amyloidosis. Blood 2008; 112:596 a-7 a (Abstract 1689).
12. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881-7.
13. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751-7.
14. Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143:369-73.
15. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440-5.
16. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125:681-700.
17. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-96.
18. Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009; 94:1044-8.
19. Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant 2003; 9:397-404.
20. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25:465-70.
21. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007; 12:664-89.
22. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
23. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110:3557-60.
24. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007; 92:1302-7.
25. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21:30-6.
26. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92:1351-8.
27. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93:295-8.
28. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28:1031-7.
29. Charaf E, Iskandar SB, Blevins A, bi-Saleh B, Fahrig S. Cardiac amyloidosis responding to bortezomib: case report and review of literature. Curr Cardiol Rev 2009; 5:228-36.
30. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114:1489-97.
31. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319-28.
32. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984; 3:107-13.
33. Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001; 24:1228-33.
34. Lown B, Graboys TB. Management of patients with malignant ventricular arrhythmias. Am J Cardiol 1977; 39:910-8.
35. Engel G, Beckerman JG, Froelicher VF, Yamazaki T, Chen HA, Richardson K, et al. Electrocardiographic arrhythmia risk testing. Curr Probl Cardiol 2004; 29:365-432.
36. UK National Institute for Health and Clinical Excellence (NICE). Chronic heart failure: management of chronic heart failure in adults in primary and secondary care; NICE Clinical Guideline 108, August 2010. [www.nice.org.uk/guidance/CG108] Accessed 20 May 2011.
37. ® (bortezomib) for Injection. Prescribing information. Cambridge, MA, USA, Issued December 2010, Rev 11.
38. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007; 9:617-24.
39. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-72.
40. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
41. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104:3520-6.
42. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109:465-70.
43. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103:2936-8.
44. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105:2949-51.
45. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109:492-6.
46. Dispenzieri A, Lacy M, Zeldenrust SR, Hayman SR, Kumar SK, Lust JA, et al. Long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone. Blood 2008; 112:612 a-3 a (Abstract 1737).
47. Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001; 113:1044-6.
48. Kristen AV, Perz JB, Schonland SO, Hansen A, Hegenbart U, Sack FU, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007; 26:1313-9.